Vanguard Group Inc. Grows Position in Vera Therapeutics, Inc. $VERA

Vanguard Group Inc. boosted its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 11.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 3,570,401 shares of the company’s stock after buying an additional 379,748 shares during the quarter. Vanguard Group Inc. owned 0.06% of Vera Therapeutics worth $180,805,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC lifted its position in Vera Therapeutics by 50.5% during the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after purchasing an additional 236 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Vera Therapeutics in the second quarter valued at about $51,000. Tower Research Capital LLC TRC lifted its position in shares of Vera Therapeutics by 192.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after acquiring an additional 2,757 shares in the last quarter. AlphaQuest LLC lifted its position in shares of Vera Therapeutics by 414.2% in the third quarter. AlphaQuest LLC now owns 5,214 shares of the company’s stock valued at $152,000 after acquiring an additional 4,200 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Vera Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,106 shares of the company’s stock valued at $157,000 after acquiring an additional 639 shares in the last quarter. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Vera Therapeutics

In other news, insider Laurence Matthew Skelton sold 1,582 shares of Vera Therapeutics stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $66,412.36. Following the sale, the insider directly owned 64,218 shares of the company’s stock, valued at approximately $2,695,871.64. The trade was a 2.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marshall Fordyce sold 22,951 shares of Vera Therapeutics stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $44.05, for a total value of $1,010,991.55. Following the completion of the sale, the chief executive officer directly owned 235,244 shares in the company, valued at $10,362,498.20. This trade represents a 8.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 56,441 shares of company stock valued at $2,416,902. 15.90% of the stock is owned by insiders.

Vera Therapeutics Price Performance

Shares of Vera Therapeutics stock opened at $36.19 on Monday. The stock’s 50-day simple moving average is $39.96 and its 200-day simple moving average is $40.35. Vera Therapeutics, Inc. has a 52 week low of $18.76 and a 52 week high of $56.05. The company has a market capitalization of $2.58 billion, a price-to-earnings ratio of -6.53 and a beta of 0.96. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period in the previous year, the company earned ($0.81) earnings per share. As a group, analysts expect that Vera Therapeutics, Inc. will post -5.54 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on VERA shares. HC Wainwright boosted their price objective on Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Wolfe Research upgraded Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective on the stock in a research report on Wednesday, March 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Monday, April 20th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $79.60.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.